Thermo Fisher Scientific is a leading biotechnology company with a stock symbol of TMO. As of my knowledge cutoff, the company has a market capitalization of over $500 billion.
Thermo Fisher Scientific has a strong financial position, with a revenue growth rate of around 10% annually. This growth is driven by the company's innovative products and services in the life sciences industry.
The company's financial performance has been consistently strong, with a net income margin of around 20%. This is a testament to the company's efficient operations and focus on delivering value to its customers.
Thermo Fisher Scientific has a solid track record of paying dividends to its shareholders, with a dividend yield of around 0.5%. This provides a relatively stable source of income for investors who hold the company's stock.
A unique perspective: Stock Broker Average Income
Financial Information
Thermo Fisher Scientific's revenue in 2023 was $42.86 billion, a decrease of -4.58% compared to the previous year's $44.92 billion.
The company's earnings in 2023 were $6.00 billion, a decrease of -13.74% from the previous year.
Thermo Fisher Scientific's revenue is expected to increase to $44,744 million in 2025, $47,940 million in 2026, and $51,289 million in 2027, according to the company's estimates.
The average estimate for the company's earnings per share (EPS) in 2025 is $23.20, increasing to $25.81 in 2026 and $29.24 in 2027.
The company's dividend yield is expected to be 0.31% in 2025 and 0.37% in 2027.
Here is a summary of the company's key financial data in 2023:
In 2023, Thermo Fisher Scientific's sales per share were $110.46, P/E ratio was 34.35, dividend yield was 0.26%, equity ratio was 47.45%, and debt ratio was 52.55%.
The company's net debt decreased from $21,233 million in 2025 to $16,808 million in 2026, and is expected to be -$4,139 million in 2027.
Thermo Fisher Scientific's research and development expenses increased from $1,413 million in 2025 to $1,551 million in 2027.
Take a look at this: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically
The company's capital expenditure increased from $1,451 million in 2025 to $1,771 million in 2027.
Thermo Fisher Scientific's shareholder's equity increased from $53,411 million in 2025 to $65,815 million in 2027.
The company's total assets increased from $104,416 million in 2025 to $113,475 million in 2027.
The average estimate for the company's revenue in 2025 is $11,290 million, increasing to $10,692 million in the current quarter and $44,744 million in 2025.
The number of analysts estimating the company's earnings in 2025 is 23, with an average estimate of $5.946 USD.
The number of analysts estimating the company's revenue in 2025 is 21, with an average estimate of $11,290 USD.
See what others are reading: Black Rifle Coffee Stock Symbol
Company News
Thermo Fisher Scientific is a company on the move, with a growth strategy that involves acquiring other companies. This approach has been effective in driving sales growth.
The company has been growing rapidly, and it's expected that the reduction in revenues due to the decline in COVID-19-related products and services will diminish or disappear in 2025.
Stock Performance
Thermo Fisher's revenue took a hit in 2023, decreasing by 4.58% to $42.86 billion compared to the previous year.
The company's earnings also suffered, dropping by 13.74% to $6.00 billion in 2023.
This decline in financial performance is a notable trend, highlighting the need for investors to stay informed about the company's progress.
Financial Performance
Thermo Fisher's revenue took a hit in 2023, decreasing by -4.58% to $42.86 billion compared to the previous year's $44.92 billion.
The company's earnings also suffered, dropping by -13.74% to $6.00 billion.
Mainz Biomed N.V., on the other hand, made a notable move by announcing a 1-for-40 reverse stock split, effective December 3.
TMO Stock Price History
The all-time high Thermo Fisher Scientific stock closing price was 662.20 on December 31, 2021, which is a remarkable achievement.
The company's stock has experienced significant fluctuations over the years. In 2021, the stock price increased by 43.54% compared to the previous year.
Here are the top 5 years with the highest annual percentage change in Thermo Fisher Scientific's stock price:
- 2013: 75.78%
- 2017: 35.03%
- 2019: 45.55%
- 2021: 43.54%
- 2007: 27.36%
These years demonstrate the company's ability to experience significant growth and recovery.
Analyst Opinions
Analyst opinions are a crucial factor in determining the potential performance of a stock. 19 analysts have given their rating for TMO stock, and the average rating is "Buy".
Analysts are optimistic about TMO's future performance, with a 12-month stock price forecast of $648.32, representing a 15.96% increase from the latest price.
The number of analysts forecasting TMO's earnings has varied over time, with 23 analysts forecasting the previous quarter, 22 for the current quarter, and 22 for the next quarter.
Here's a breakdown of the average earnings estimates for TMO:
The average earnings estimates have been steadily increasing over time, reflecting analysts' growing confidence in TMO's performance.
Company Profile
Thermo Fisher Scientific is a supplier of scientific laboratory products, instruments, software, and other tools. The company was formed in a tax-free stock-for-stock merger of Thermo Electron Corporation with Fisher Scientific International Inc. in 2006.
Thermo Fisher Scientific provides services through various brands including Thermo Fisher, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. It aims to increase productivity in laboratories and improve patient health through diagnostics and therapy development.
The company caters to four main segments: industrial and applied research, diagnostics and healthcare, academic and government research, and pharmaceuticals and biotechnology.
Here's an interesting read: Fisher Investments Founder
Company Profile
Thermo Fisher Scientific Inc. is a supplier of scientific laboratory products, instruments, software, and other tools. The company was formed in a tax-free stock-for-stock merger of Thermo Electron Corporation with Fisher Scientific International Inc. in 2006.
The company provides services through various brands including Thermo Fisher, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.
Thermo Fisher Scientific caters to four main segments: industrial and applied research, diagnostics and healthcare, academic and government research, and pharmaceuticals and biotechnology.
A unique perspective: Black Rock Stock Symbol
Management
Thermo Fisher Scientific has a diverse and experienced management team. Marc N. Casper serves as the Chairman, President & Chief Executive Officer.
The company's leadership includes several key executives who oversee various aspects of the business. Joseph Holmes is the Chief Accounting Officer & Vice President, while Stephen Williamson is the Chief Financial Officer & Senior Vice President.
The company's management team also includes Lisa P. Britt as the Chief Human Resources Officer & Senior VP, and Ryan Snyder as the Chief Information Officer & Senior Vice President. Alan B. Sachs serves as the Chief Medical Officer, and Michel Lagarde is the Chief Operating Officer & Executive Vice President.
Here is a list of the company's executives:
The company also has several independent directors, including Nelson J. Chai, R. Alexandra Keith, and James C. Mullen. These directors provide oversight and guidance to the company's management team.
Frequently Asked Questions
Who is Thermo Fisher's biggest competitor?
Thermo Fisher's biggest competitors are Danaher Corp and Becton Dickinson and Co, both of which are large life sciences companies with significant market presence.
Is Thermo Fisher in the S&P 500?
Yes, Thermo Fisher Scientific is a member of the S&P 500 index, as well as several other notable stock market indices. This membership indicates the company's significant market presence and financial performance.
Featured Images: pexels.com
